October 2017 Newsletter

October 25, 2017:

2017 ESCRS Meeting Showcases IOLs, Diagnostics; Speakers Wrestle with Cost of Health Care

This year’s conference drew about 10 thousand attendees to Lisbon, Portugal.

October 25, 2017:

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

In the company’s Phase III study, 93 percent of subjects improved on an obstacle course designed to gauge light sensitivity.

October 25, 2017:

US District Court Invalidates Four of Allergan’s Restasis Patents, Criticizes Deal with Tribe

CEO Brent Saunders says allowing patent challenges through the courts and patent office is an unfair burden.

October 25, 2017:

Shire Sues Allergan over Bundling Tactics for Restasis

Suit claims ‘anticompetitive scheme’ has hindered Xiidra’s entry into Medicare Part D plans.

October 25, 2017:

Imprimis Offers Compounded Alternative to Restasis

Formulations include 'Klarity Drops,' a patented formulation developed by Richard Lindstrom, MD.

October 25, 2017:

J&J Vision Acquires Online Contact Lens Business Sightbox

Sightbox will continue to provide lenses from all major manufacturers.

October 25, 2017:

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

The agency’s target action date for deciding whether to approve the drug is Feb. 25.

October 25, 2017:

Aerie Acquires Envisia’s PRINT Technology for $25M to Advance Retinal Program

Aerie said it initially plans to use the sustained-release technology with its wet AMD candidate.

October 25, 2017:

Market Report: Retinal Pharma Market Expected to Grow 6.2 Percent through 2022

The introduction of biosimilars and new therapeutic products over the next three years may disrupt the anti-VEGF segment.

October 25, 2017:

Market Scope Weekly Polls

October 25, 2017:

FDA Warns that Vancomycin Eye Injections May Lead to Blindness

The agency said many ophthalmologists use it during cataract surgery in an attempt to prevent endophthalmitis.

October 25, 2017:

Bribery Trial Testimony Focuses on Melgen’s Billing for Lucentis

The retina specialist charged Medicare per eye patient, even though he repackaged single-use Lucentis vials into multiple syringes to treat several patients.

October 25, 2017:

2017 ESCRS Meeting: Glaucoma Day Program Focuses on Fiscal Burden of Overdiagnosis

Panelists discuss IOP’s value in referring patients.

October 25, 2017:

2017 ESCRS Meeting: Glaucoma Sessions Analyze Results of MIGS Competitors

Tailored stent selection is critical, one speaker said.

October 25, 2017:

2017 ESCRS Meeting: Sessions Yield Positive Results, High Praise for Trifocal, EDOF Lenses

Surgeons reported high levels of patient satisfaction and glasses independence in comparison studies.

October 25, 2017:

2017 ESCRS Meeting: PREMED Study Results Favor Combo Therapy to Prevent Post-Cataract CME

The trial is designed to evaluate different preventive strategies in diabetic and non-diabetic patients.

October 25, 2017:

2017 ESCRS Meeting: Presenters Review FEMCAT Study Results as FLACS Debate Continues

There were no statistically significant differences using FLACS or phaco for all studied outcome measures, the speaker said.

October 25, 2017:

2017 ESCRS Meeting: Surgeons Scrutinize Economics of FLACS

Speaker says public systems will not pay more for FLACS than conventional phaco.

October 25, 2017:

2017 ESCRS Meeting: ISOP Conference Highlights Latest Research in Presbyopia Treatment

Speakers described their use of the KAMRA and Raindrop inlays.

October 25, 2017:

2017 ESCRS Meeting: Surgeons Explore Various Clinical Evidence of SMILE Procedure

Topics included patient outcomes versus LASIK and complications, such as suction loss.

October 25, 2017:

2017 ESCRS Meeting: Ophthalmology Futures Forum Tackles Problems with Dry AMD

Speakers questioned when and whether patients should be treated, as well as what technology to use.

October 25, 2017:

2017 ESCRS Meeting: New Diagnostic Instruments, Femtosecond Laser Prototypes Energize Exhibit Hall

Advanced microscopes and OCT devices were among the instruments showcased at the meeting.

October 25, 2017:

2017 ESCRS Meeting: ‘Building a New Eye’ Session Shows Progress in Regenerative Eye Therapy

Speakers provided updates on tissue-engineered corneas, limbal cell transplantation, and regeneration of the crystalline lens.

October 25, 2017:

Novartis Returns OUS Rights for Jetrea to ThromboGenics

Novartis will pay ThromboGenics €53.7 million in cash and make an equity investment of €10 million.

October 25, 2017:

Preview: 2017 AAO Meeting to Kick Off with Seven Subspecialty Day Programs

The conference is the largest ophthalmic event in the world and drew 25,430 attendees in 2016.

October 25, 2017:

Market Scope’s Must-See Sessions at the 2017 AAO Meeting

October 25, 2017:

Ophthalmic Funding Briefs

October 25, 2017:

October 2017 News Briefs

Social media